Madrigal Pharmaceuticals Files Q1 2025 10-Q Report

Ticker: MDGL · Form: 10-Q · Filed: May 1, 2025 · CIK: 1157601

Sentiment: neutral

Topics: 10-Q, quarterly-report, pharmaceuticals

TL;DR

Madrigal Pharma dropped its Q1 2025 10-Q. Check financials.

AI Summary

Madrigal Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The company, headquartered in West Conshohocken, PA, reported its financial status for the first quarter of 2025. Key financial data and business operations for this period are detailed within the filing.

Why It Matters

This filing provides investors and analysts with the latest financial performance and operational updates for Madrigal Pharmaceuticals, crucial for assessing the company's current health and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Madrigal is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The Conformed Period of Report is 20250331, meaning the filing covers the period ending March 31, 2025.

When was this 10-Q report filed with the SEC?

The report was filed on 20250501.

What is Madrigal Pharmaceuticals' Standard Industrial Classification code?

The SIC code is [2834], which corresponds to Pharmaceutical Preparations.

What was Madrigal Pharmaceuticals' former company name?

The company's former name was SYNTA PHARMACEUTICALS CORP.

On what date did the company change its name?

The date of the name change was 20010815.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 1, 2025 regarding MADRIGAL PHARMACEUTICALS, INC. (MDGL).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing